These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16806410)

  • 21. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
    Guzzo TJ; Vira MA; Neway W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
    Urology; 2007 Jun; 69(6):1147-51. PubMed ID: 17572204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of prostate cancer pathologic features in Chinese populations.
    Chuang AY; Chang SJ; Horng CF; Tsou MH
    Urology; 2007 May; 69(5):915-20. PubMed ID: 17482934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
    Sankin A; Tareen B; Lepor H
    Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.
    Yee DS; Shariat SF; Lowrance WT; Maschino AC; Savage CJ; Cronin AM; Scardino PT; Eastham JA
    BJU Int; 2011 Aug; 108(4):502-7. PubMed ID: 21050364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Routinely reported 'equivocal' lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes.
    Galiabovitch E; Hovens CM; Peters JS; Costello AJ; Battye S; Norden S; Ryan A; Corcoran NM
    BJU Int; 2017 Apr; 119(4):567-572. PubMed ID: 27431748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
    Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ
    Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
    J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.